Meeting
2018 Genitourinary Cancers Symposium
Cabozantinib for metastatic castration-resistant prostate cancer (mCRPC) following docetaxel: Combined analysis of two phase III trials.
Authors
Gregory Russell Pond
McMaster University, Hamilton, ON, Canada
Gregory Russell Pond , Guru Sonpavde , Karim Fizazi , Johann S. De Bono , Ethan M Basch , Howard I. Scher , Matthew Raymond Smith
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 225)
DOI
10.1200/JCO.2018.36.6_suppl.225
Abstract #
225
Poster Bd #
L1
Abstract Disclosures
Similar Posters
Poster
2015 Genitourinary Cancers Symposium
Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E)
First Author: Ethan M. Basch
Poster
2011 Genitourinary Cancers Symposium
Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Estimating mean overall survival (OS) for health economic analyses from a phase III trial (TROPIC).
First Author: Stephane Oudard
Poster
2016 ASCO Annual Meeting
Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration resistant prostate cancer (mCRPC) treated on SWOG Study S0421.
First Author: Gregory Russell Pond
Poster
2012 Genitourinary Cancers Symposium
Prognostic factors for survival in the phase III TROPIC trial.
First Author: A. Oliver Sartor